Primary haemophagocytic lymphohistiocytosis (HLH) diseases are a collection of inherited genetic disorders that cause the syndrome of HLH. Great advances have been made in the last 20 years with regard to the discovery of many of the genetic aetiologies of disease. Several advances have also been made on the clinical stage. Accurate screening diagnostics for primary HLH diseases that are superior to traditional Natural Killer cell function testing have been developed and are now available in many countries. There is now grounded clinical experience on which to base routine treatment decisions for patients with HLH. Newer approaches to allogeneic haematopoietic cell transplantation have increased overall patient survival. Despite these advances, however, there is still much work to be done to further improve patient care. This 'How I Treat' article will focus on summarizing current diagnostic, treatment and transplant strategies for patients with primary HLH diseases.
Introduction
Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized most often by fevers, cytopenias and hepatosplenomegaly. Other manifestations include rash, hepatitis or acute liver failure, coagulopathy and central nervous system (CNS) involvement, which can include altered mental status, seizures, focal deficits and other complications. The syndrome of HLH is simply that, a syndrome characterized by the constellation of clinical manifestations described. Patients are said to have primary HLH if they are found to have a genetic disease that causes HLH. Patients may also be diagnosed with primary HLH if a genetic disease is strongly suspected despite lack of a confirmed genetic diagnosis, such as in cases of recurrent or recalcitrant HLH, in the context of abnormal Natural Killer (NK) cell degranulation, function, or perforin expression, or in the setting of a family history of HLH.
Over the last 2 decades, significant advances have been made with regard to the genetic understanding of primary HLH diseases. These discoveries have led to significant improvements in patient diagnostics. The last 2 decades have also witnessed organized trials of HLH therapy that have yielded good clinical experience on which to base routine treatment decisions for patients with HLH. Curative treatment with allogeneic haematopoietic cell transplantation (HCT) has also come a long way in the last 20 years, and reduced intensity conditioning (RIC) approaches have improved survival.
Despite these advances, there is still much work to be done to further improve patient care. Optimal diagnostic screening test algorithms need to be more widely adapted in order to compliment or replace older assays, such as NK cell cytotoxic function testing performed with chromium release assays. More targeted and less toxic therapies are needed for the routine treatment of HLH. RIC approaches need to be improved to yield more robust sustained levels of donor chimerism following allogeneic HCT. Fortunately, there are several recently completed or ongoing clinical trial endeavours that have evaluated or are evaluating more targeted HLH therapies and RIC approaches for allogeneic HCT. These studies will probably advance the treatment of HLH in the next 5-10 years. However, standard-of-care approaches are still needed for patients who are not enrolled on clinical trials for HLH or for transplant. This "How I Treat" article will focus on summarizing current diagnostic, treatment and transplant strategies for patients with primary HLH diseases.
et , 2002 Janka & Schneider, 2004) . Many clinicians generally consider patients to have HLH if 5 out of 8 criteria are met, including having fever, splenomegaly, cytopenias in at least 2 lineages, hypertriglyceridaemia and/or hypofibrinogenaemia, haemophagocytosis observed in bone marrow, spleen, lymph nodes, liver or other tissues, low or absent NK-cell activity, elevated ferritin, and elevated levels of soluble interleukin (IL) 2 receptor (sIL2-R) (Table I) . However, these criteria have several shortcomings. Many patients with HLH may not meet 5/8 criteria early during disease, and some patients present with incomplete or atypical disease manifestations, such as acute liver failure or isolated CNS involvement. Notably, approximately 17% of patients with primary HLH were observed to have incomplete or atypical presentations in a recent large German cohort (Ammann et al, 2017a) . Additionally, some patients with severe infections, rheumatological diseases, haematological malignancies or primary immune deficiencies may meet criteria and be misdiagnosed as having only HLH until such time as an underlying disease process becomes more obvious. In the same German cohort, only 36% of patients with 'full HLH' were ultimately found to have primary HLH (Ammann et al, 2017a) . Many of the criteria themselves are misconstrued to be 'gold standard' features of HLH. For instance, some clinicians mistakenly perceive that the absence of haemophagocytosis makes a diagnosis of HLH unlikely, or that the observation of haemophagocytosis means that a patient certainly has HLH. However, many patients with HLH will lack haemophagocytosis, especially early during disease, and the observation of haemophagocytosis has been observed to have poor specificity (Goel et al, 2012; Gupta et al, 2008; Ho et al, 2014; Lao et al, 2016) .
Laboratory testing for the syndrome of HLH classically relies on measuring levels of triglycerides, fibrinogen, ferritin, and soluble IL-2 receptor (sIL2-R). Importantly, the NK cell function test has historically been considered to be a gold standard diagnostic test. However, the utility of this test to screen for genetic HLH disorders has recently been questioned, and the diagnostic accuracy appears to be somewhat poor compared to flow cytometric screening strategies (discussed later) (Rubin et al, 2017) . Newer adjunctive testing may include measurement of levels of CXCL9, which indicate interferon-gamma (IFN-c) pathway activity, or IL-18, indicative of inflammasome activity, which are gaining in use. Examining the ratio of IL-18 to CXCL9 may serve to differentiate patients with primary HLH from patients with rheumatological diseases and macrophage activation syndrome, except for patients with XIAP deficiency and NLRC4 mutations who have high levels of IL-18 (Tsoukas et al, 2017) . Flow cytometric measurement of T cell upregulation of HLA-DR was very recently and eloquently shown to be an excellent indicator of HLH (Ammann et al, 2017b) . Some centres use this marker, which is easy to measure by flow cytometry, in place of sIL2-R.
Thus, great care must be taken when considering a diagnosis of the syndrome of HLH. Careful evaluations for alternative diagnoses, such as infection, rheumatological disease and malignancy should be pursued in all patients until such time that a genetic diagnosis of a primary HLH disease is clear. Importantly, the detection of an infection can be also observed in primary HLH and frequently represents the trigger of the HLH episode. Consideration should also be given regarding testing for other primary immune deficiencies, such as severe combined immune deficiency (SCID) and chronic granulomatous disease (CGD) (Bode et al, 2015) . The authors generally approach the evaluation of patients with suspected HLH as summarized in the algorithm in Fig 1. 
Genetics of primary HLH
The first genetic cause of familial HLH was discovered by Stepp et al (1999) when the authors found that patients with mutations in PRF1 developed HLH. PRF1 encodes perforin, which is a critical component of cytotoxic lymphocyte granule-mediated cytotoxicity. Granule-mediated cytotoxicity encompasses the process by which NK cells and cytotoxic T lymphocytes kill target cells via polarized delivery of cytotoxic granule contents to the immunological synapse space shared with a target cell (Fig 2) (de Saint Basile et al, 2010; Voskoboinik et al, 2010) . Perforin is contained within cytotoxic granules, and once granule contents are extruded by the NK cell or cytotoxic T lymphocyte, perforin oligomerizes on the surface of the target cell and creates pores that allow the entry of cytotoxic granule contents (granzymes and other proteases) into the target cell (Voskoboinik et al, 2010) . Target cell death then ensues and, remarkably, evidence of apoptosis can be observed in as little as 2 min of perforin permeabilization (Lopez et al, 2013) .
Several other genetic diseases have been discovered to cause HLH by also crippling granule-mediated cytotoxicity Table I . Criteria commonly used to aid in the diagnosis of haemophagocytic lymphohistiocytosis (HLH). A diagnosis is consistent with HLH if 5/8 of the listed criteria are met, or if the patient has a molecular diagnosis of genetic HLH.
1. Fever ≥38Á5°C 2. Splenomegaly 3. Cytopenias (affecting at least 2 of the below)
Haemoglobin <90 g/l (in infants <4 weeks: haemoglobin <100 g/l) Platelet count <100 9 10 9 /l Neutrophil count <1Á0 9 10 9 /l 4. Hypertriglyceridaemia (fasting, >3Á0 mmol/l) and/or hypofibrinogenaemia (<1Á5 g/l) 5. Haemophagocytosis in bone marrow, spleen, lymph nodes, liver or other tissue 6. Low or absent Natural Killer (NK) cell activity 7. Ferritin > 500 lg/l 8. Elevated soluble CD25 (soluble interleukin 2 receptor):
> 2400 u/ml or elevated based on the laboratory-defined normal range (Table II) . Mutations in UNC13D, STXBP2, STX11, RAB27A, LYST and AP3B1 all cause deficiencies in proteins which are necessary for proper cytotoxic granule trafficking to, or fusion with, the cell membrane (Barbosa et al, 1996; Cote et al, 2009; Enders et al, 2006; Feldmann et al, 2003; Menasche et al, 2000; zur Stadt et al, 2009 zur Stadt et al, , 2005 Crippling of cytotoxic lymphocyte granule-mediated cytotoxicity is thought to lead to HLH by multiple mechanisms. Following a normal infection, there is generally a targeted immune response against the pathogen/pathogen-infected cells, which is followed by contraction of the immune response once the inciting infection is cleared. However, in patients with HLH, there is defective killing of antigen-presenting cells, which probably contributes to a state of excessive activation and proliferation of both antigen-presenting cells and effector cells. It has been shown that a prolonged synapse time exists between murine perforin-deficient or granzyme A/B-deficient cytotoxic lymphocytes and target cells, resulting in overproduction of inflammatory cytokines that probably play crucial roles in the development of HLH (Jenkins et al, 2015) . In addition, several of the normal processes of immune response down-regulation are also hindered by the lack of normal granule-mediated cytotoxicity. Impairment of elimination of CD4+ T cells by NK cells, elimination of cytotoxic T lymphocytes by granule-containing T-regulatory cells, and CD8+ T cell fratricidal processes have all been implied to contribute to HLH pathology (Janka & Lehmberg, 2013) . Interestingly, some granule contents that enter the target cell may also directly inhibit release of viable virus (Voskoboinik et al, 2010) . Due to defects in antigen clearance and effector cell control, a vicious cycle of perpetuating hyperinflammation is thought to ensue, which leads to systemic hypercytokinaemia and widespread tissue damage by infiltrating activated immune system cells.
Several other genetic diseases are also considered to be Primary HLH diseases. Patients with X-linked lymphoproliferative disease type 1 (XLP1) have mutations in SH2D1A (Coffey et al, 1998; Nichols et al, 1998; Sayos et al, 1998) . SH2D1A encodes a small tyrosine kinase, SLAM-associated protein (SAP) that mediates signalling of the SLAM family of receptors. Defects in SAP lead to several immunological abnormalities. Lack of SAP leads to defective 2B4-mediated cytotoxicity, absence of invariant NKT cell development, defective T cell restimulation-induced cell death and other humoral and cellular abnormalities (Cannons et al, 2011; Nichols et al, 2005; Pasquier et al, 2005; Snow et al, 2009) . Patients with XLP1 develop HLH almost exclusively in response to Epstein-Barr virus (EBV), and are also prone to developing lymphoma, hypogammaglobulinaemia, aplastic anaemia, and vasculitis.
Patients with X-linked lymphoproliferative disease type 2 (XLP2) have mutations in XIAP (previously termed BIRC4), which encodes X-linked inhibitor of apoptosis (XIAP) (Rigaud et al, 2006) . Deficiency of XIAP is not associated with defects in cytotoxicity. XIAP deficiency leads to several immunological abnormalities, including dysregulated tumour necrosis factor (TNF) receptor signalling and inflammasome function, defective nucleotide oligomerization domain (NOD) signalling and increased cell susceptibility to death following a variety of stimuli (Damgaard et al, , 2012 Lawlor et al, 2017; Marsh et al, 2010a; Rigaud et al, 2006; Yabal et al, 2014) . Patients with XIAP deficiency may develop several complications besides HLH, including atypical/mild HLH-like episodes, inflammatory bowel disease, recurrent infections, hypogammaglobulinemia and, rarely, other complications, such as uveitis, fistulating skin disease, granulomatous hepatitis or granulomatous and lymphocytic interstitial lung disease (GLILD) (Basiaga et al, 2015; Marsh et al, 2010a; Pachlopnik Schmid et al, 2011; Rigaud et al, 2006; Speckmann et al, 2013; Steele et al, 2016) .
Patients with NLRC4 mutations also develop HLH, due to constitutively active NLRC4 inflammasome function (Canna et al, 2014; Romberg et al, 2014) . These patients also develop inflammatory bowel disease and other complications. Interestingly, like patients with XIAP deficiency, HLH episodes in patients with NLRC4 mutations are not due to an abnormal cytotoxicity but are due to a hyperactivation of the inflammasome.
Still other genetic diseases may be associated with HLH including mutations in MAGT1, ITK, and CD27. These diseases are associated with poor handling of EBV and, notably, patients with these diseases are also prone to the development of lymphoma (Alkhairy et al, 2015; Huck et al, 2009; Li et al, 2011 Li et al, , 2014 Linka et al, 2012; Salzer et al, 2013; Stepensky et al, 2011; van Montfrans et al, 2012) .
Consideration of HLH in other genetic disorders
It is important to mention that HLH may also occur in the setting of other genetic disorders, particularly other primary immune deficiencies. HLH has been described in a number of patients with SCID and CGD (Bode et al, 2015) . HLH in these cases is usually associated with infection. HLH has been observed in the context of various combined immune deficiency (CID) conditions, Wiskott-Aldrich Syndrome, DiGeorge Syndrome, patients with IKBKG mutations, GATA2 mutations, STAT1 gain of function mutations, and others (Bode et al, 2015; Leiding et al, 2018; Spinner et al, 2016) . Features of HLH may also occur in a number of genetic metabolic conditions including most notably lysinuric protein intolerance (Duval et al, 1999) .
Diagnostic screening tests for primary HLH diseases
As part of the initial work up of patients who are suspected to have HLH, rapid screening tests can screen for genetic causes of HLH (Table II, Fig 3) . Importantly, positive screening tests can support clinical decisions regarding HLH (Ammann et al, 2017a) .
Flow cytometric screening tests that directly measure lymphocyte expression of proteins of interest are available for perforin, SAP, and XIAP. Results are typically available within a few days. The sensitivity for these assays to detect patients with perforin deficiency, XLP1 or XLP2 has been reported to be 87-96% using laboratory-defined normal ranges (Abdalgani et al, 2015; Gifford et al, 2014) . CD107a assays which quantitate the degranulation of NK cells or T cells by flow cytometry have been reported to have a sensitivity of 94-96% when using receiver-operator characteristic curve-defined diagnostic cut-offs to detect patients with degranulation pathway gene mutations (Fig 2) (Bryceson et al, 2012; Rubin et al, 2017) . Importantly, a direct comparison of perforin and CD107a tests against NK cell cytotoxic function testing revealed that the flow cytometric tests perform much better with regard to identifying patients with PRF1 mutations or degranulation pathway mutations (UNC13D, STXBP2, STX11, RAB27A, LYST and AP3B1). The authors do not recommend that NK cell function testing be used as part of the diagnostic evaluation of patients with suspected HLH, and instead recommend perforin and CD107a testing, along with SAP and XIAP in male patients. XIAP testing should also be considered in female patients with HLH for whom a genetic diagnosis has not been found, as female carriers may have skewed lionization and develop HLH (Holle et al, 2015; Yang et al, 2015) . A functional screen for XIAP deficiency is available via evaluation of NOD2 signalling (Ammann et al, 2014) , and IL-18 levels can be helpful as a screening tool for patients with XIAP deficiency or NLRC4 mutations. Also, hair microscopy (for RAB27A, LYST and AP3B1) or polymorphonuclear cell microscopy (for LYST) can provide a very fast diagnosis and allow targeted sequencing. 
Treatment of HLH
Once a diagnosis of HLH is made, therapy should be started as soon as possible. Early initial treatment of patients with steroids can also be considered while awaiting the results of diagnostic studies, with the exception that steroid treatment should be delayed until evaluations for malignancy are obtained so as not to interfere with a diagnosis of leukaemia/ lymphoma, particularly in adults.
The treatment of HLH generally consists of potent immunosuppressive and chemotherapeutic agents, and standard-of-care approaches have not dramatically changed in the last 20 years (Table III) . A regimen of dexamethasone and etoposide has been the mainstay of treatment in most of North American and Europe, based on the HLH-1994 and HLH-2004 study protocols (Bergsten et al, 2017; Bryceson et al, 2007; Henter et al, 2002) . The HLH-2004 protocol incorporated the early administration of ciclosporin, but there has been no clear benefit related to early administration of ciclosporin (Bergsten et al, 2017) . Due to the notable complications of ciclosporin, such as posterior reversible encephalopathy syndrome (PRES) and renal toxicity, the authors do not recommend the routine use of ciclosporin early in HLH treatment, though some clinicians find it useful for maintaining disease remission after HLH has improved, until allogeneic HCT. Care should be exercised with regard to dosing and monitoring of levels. When neurological symptoms occur during ciclosporin treatment, one should consider and rule out CNS manifestations of HLH (see below) before making the diagnosis of ciclosporin-induced PRES. Approximately 53% of patients can be expected to achieve a complete response with steroid and etoposide treatment at 2 months, and approximately 32% of patients can be expected to achieve a partial response (Henter et al, 2002 ). An alternative regimen was pioneered in France that contained steroids and anti-thymocyte globulin (ATG). Seventy-three per cent of patients achieved a complete response with this approach, and 24% of patients achieved a partial response (Mahlaoui et al, 2007) .
The authors generally recommend that routine therapy for patients who aren't enrolled on to a clinical trial should consist of steroids and etoposide or ATG based on the above published experiences. Therapy with dexamethasone and etoposide should be tailored to individual patients based on disease activity and response. It is not necessary to exactly follow the HLH-1994 or HLH-2004 roadmaps. Some patients will have a rapid response to treatment, and treatment in those patients should be weaned more rapidly than prescribed on the clinical trials. Other patients may need prolonged tapers or the addition of other drugs. The authors generally initiate dexamethasone at 10 mg/m 2 per day and start etoposide with a weekly or twice weekly frequency, but this is dependent on HLH activity and patient tolerance. Care should be taken to monitor for etoposide-induced marrow suppression, as hypoplasia and aplasia can occur. Repeating a bone marrow after several weeks of therapy can be helpful to evaluate for hypoplasia in patients who have made significant improvements in HLH disease manifestations but have re-developed worsening cytopenias after an initial improvement. The authors generally attempt to wean the dexamethasone weekly or every other week, again depending on HLH activity in each individual patient. Etoposide is generally continued for 1-2 months by the authors before considering a stop of treatment or a wean to every other week frequency. Treatment should not be continued indefinitely unless patients have active disease. The authors have different practices regarding the use of ciclosporin. One author uses ciclosporin once HLH is in remission while awaiting allogeneic HCT, while the other doesn't use it. It is worth mentioning that the objective of using ciclosporin is to reduce the risk of relapse and not to delay HCT. The author that uses ciclosporin has observed that in some cases, its reduction or interruption due to toxicity has been followed by relapses, suggesting that ciclosporin has some activity in preventing relapses. The treatment of associated infections that can trigger the HLH episode is important and has to be adapted to the causal microorganism. Rituximab should be given in patients with EBV-associated HLH (Chellapandian et al, 2013) . Some patients will develop flares of HLH as therapy is weaned, and will need intensification of therapy with increases in steroid dose and/or escalation of etoposide frequency and/or switch to serotherapy, such as ATG or alemtuzumab. Frequent monitoring of blood counts, liver enzymes, bilirubin, fibrinogen, etc., are helpful to gauge responses, which can generally be observed within a week of starting therapy, and are also useful to monitor for disease flares. Weekly or twice weekly monitoring of sIL2-R or other HLH-associated inflammatory markers can be very helpful. If steroids and ATG are used, therapy should also be tailored to the individual patient. ATG is given at 5 to 10 mg/ kg 9 5 days, depending on the severity of the disease. High doses of methylprednisolone (4 mg/kg) are classically used during ATG therapy and then progressively tapered. The first dose of ATG, which can induce the simultaneous killing of a huge number of activated T cells, can be associated with a severe cytokine storm. The author that uses this strategy performs very slow infusion of ATG on the first day of treatment together with low fluid intake and close monitoring of the patient. Once remission is achieved, ciclosporin is used with steroids during the maintenance therapy before allogeneic HCT. Dexamethasone may be preferred to methylprednisolone because it has a better penetration into the cerebrospinal fluid (CSF) (Inaba & Pui, 2010) and could therefore potentially better prevent CNS involvement.
All patients who are diagnosed with HLH should have brain imaging with magnetic resonance imaging (MRI) as well as a lumbar puncture to evaluate for CNS involvement, regardless of having any CNS manifestations of HLH or not. CNS disease occurs in 30-73% of HLH patients and can be very severe (Deiva et al, 2012; Haddad et al, 1997; Jovanovic et al, 2014; Trottestam et al, 2011; Yang et al, 2010) . The authors generally defer these evaluations during the initial acute disease presentation when patients may be unstable and/or profoundly coagulopathic and thrombocytopenic, but will complete these evaluations later once patients are stable. CNS disease should be diagnosed in any symptomatic patients, and/or based on brain imaging observations and/or CSF abnormalities. The most frequently observed MRI findings are bilateral, multifocal hyperintensities observed on T2-weighted imaging (Deiva et al, 2012) . Increased white blood cell count, elevated protein or observation of activated lymphocytes, macrophages or haemophagocytosis on pathological examination of CSF also indicate active CNS HLH. The treatment of CNS HLH has been recently reviewed , and treatment with intrathecal steroids and methotrexate should generally be pursued in patients with CNS HLH (in addition to systemic treatments). The authors generally continue intrathecal treatment until the CSF evaluations have normalized or have nearly normalized. The addition of serotherapy with ATG or alemtuzumab can be also useful in relapsing or severe CNS involvement (unpublished observations). Of note, CNS HLH may relapse in the early post-transplant period in patients who undergo allogeneic HCT, and post-transplant screening lumbar punctures can be considered after early haematopoietic recovery Lounder et al, 2017) .
There have been recent trials of a 'Hybrid Immunotherapy' approach for HLH (HIT-HLH) in North America and Europe that combined steroids, etoposide and ATG (NCT01104025). However, published results are not yet available. Additionally, at the current time, several other trials are being conducted for HLH. An anti-IFN-cmonoclonal antibody is being trialled at several centres in North America and Europe (NCT01818492). Alemtuzumab is being trialled for the treatment of HLH in France (NCT02472054). Tocilizumab is being evaluated at a single centre in Philadelphia (NCT02007239), and a pilot study of ruxolitinib for secondary HLH is open at a single centre in Michigan (NCT02400463). A trial of recombinant human IL-18 binding protein is being trailed specifically for patients with XIAP deficiency and NLRC4 mutations (NCT03113760). The results of these studies may alter the treatment of patients with HLH in the near future, but at the present time, the authors generally recommend that patients with uncomplicated HLH be treated with dexamethasone and etoposide or ATG. There are numerous small reports of alternative therapies for patients with HLH, such as agents directed against IL-1beta, IL-6, TNF, etc., but they lack large-scale evaluations and are beyond the scope of this article.
Concomitant therapies for patients with primary HLH
Care should be taken to treat any associated trigger of HLH. For example, cytomegalovirus (CMV) should be treated with ganciclovir or other anti-viral treatment, and rituximab can be considered for patients with EBV. Care should also be taken with regard to providing appropriate anti-microbial prophylaxis to patients with HLH. The authors generally recommend anti-pneumocystis jirovecii and anti-fungal prophylaxis for all patients. Many patients should also receive anti-viral prophylaxis depending on age and previous exposures. Intravenous immunoglobulin (IVIG) supplementation is also generally recommended in the setting of prolonged immunosuppressive treatments. Patients with HLH often develop complicating infections, and should be monitored closely and treated aggressively. Infusions of red cells, platelets and cryoprecipitate are often needed in the acute phase of HLH. Critical care support may be needed as well.
Refractory HLH
Some patients will be intolerant of therapy, or will have disease that is refractory even to intensified therapies, and will require salvage therapies. Unfortunately, there is very little literature on which to base salvage therapy decisions. A working group within the Histiocyte Society recently reviewed the existing literature regarding salvage therapy of patients with HLH that was refractory to steroids and etoposide or steroids and ATG (Marsh et al, 2017a) . Limited evidence was found for anakinra, ATG, alemtuzumab and liposomal doxorubicin. Anakinra was used in three patients with cytophagic histiocytic panniculitis and secondary HLH or rheumatological disease-associated HLH, and all patients were reported to have achieved a complete response without serious complications (Behrens et al, 2006; Miettunen et al, 2011) . Anakinra is also often used in HLH associated with systemic juvenile idiopathic arthritis (Schulert & Grom, 2015) . However, there is no evidence in the literature at the present time to support the use of anakinra for primary HLH.
Nine patients received rabbit ATG (Genzyme) as a second line therapy following steroids and etoposide or following a previous course of steroids and ATG. Eight patients achieved a complete response (Mahlaoui et al, 2007) .
Alemtuzumab was reported for the salvage therapy of 24 paediatric and young adult patients with refractory HLH (Gerard et al, 2012; Marsh et al, 2013a; Strout et al, 2010) . Sixty-seven per cent of patients were reported to achieve a partial response, and the rest had no response. Notably, CMV and adenovirus viraemias occurred in 23-32% of patients following alemtuzumab. Fever and transient worsening of cytopenias, possibly due to the simultaneous killing of a huge number of activated T cells, were also observed in some patients.
A regimen consisting of liposomal doxorubicin plus steroids and etoposide (DEP) was also reported in adult patients with refractory HLH . When only accounting for patients who did not have malignancy, 26 out of 32 (81%) patients achieved a complete or partial response. While the report suggested that this might be a useful approach for patients with refractory HLH, it is difficult to determine how much the liposomal doxorubicin directly impacted outcomes because patients were also being treated with steroids and etoposide.
Overall, the authors most often recommend alemtuzumab for the treatment of patients with refractory HLH. Alemtuzumab can also be considered as an initial therapy when the patient presents with very severe HLH with life-threatening complications. Careful monitoring for viral reactivations is needed, and the authors recommend weekly blood polymerase chain reaction monitoring for EBV, CMV and adenovirus, and other viruses if clinically indicated. Broadspectrum anti-microbial prophylaxis and IVIG replacement are also indicated.
Allogeneic haematopoietic cell transplantation for primary HLH
Most patients with primary HLH due to PRF1, UNC13D, STXBP2, STX11, RAB27A, LYST and SH2D1A mutations are optimally treated with allogeneic HCT. The transplant indications for patients with XLP2 or NLRC4 mutations remain controversial or unclear, respectively, and the indication for Hermansky-Pulak syndrome type 2 is also unclear. Allogeneic HCT should ideally be performed when patients are in remission from HLH as outcomes are generally better. Outcomes have even been shown to be better in patients with XLP1 who have never developed HLH compared with those who had a history of HLH (Booth et al, 2011) . These data suggest that allogeneic HCT should be performed for asymptomatic patients with genetic HLH disorders before the onset of HLH, but this remains controversial. Importantly, while transplant should ideally be performed when HLH is in remission, if this is not possible, allogeneic HCT should still be attempted. For patients with refractory CNS HLH, allogeneic HCT should also be attempted as it may halt CNS disease (though fixed defects may not reverse) . As mentioned previously, patients with a history of CNS HLH may develop a CNS HLH relapse early post-transplant, and should be monitored for CNS HLH (Lounder et al, 2017) . Screening lumbar punctures can also be considered in the early post-transplant period following initial haematopoietic recovery Lounder et al, 2017) .
Like all transplant patients, a human leucocyte antigen (HLA)-matched sibling donor is the preferred donor for patients with HLH due to minimized risk of acute graftversus-host disease, but genetic evaluation should be performed to make sure that the sibling is not also affected by genetic HLH disease. At this time, it is the authors' practice to use siblings who carry a single allele mutation in an HLHassociated gene when the disease is known to be caused by biallelic mutations. Female carriers of X-linked diseases are also acceptable, though the authors recommend evaluating protein expression in female carriers of mutations in SH2D1A and XIAP to ensure there is no evidence of severely skewed X chromosome lyonisation. An HLA-matched unrelated donor is the preferred alternative if an HLA-matched sibling is not available. If no HLA-matched unrelated donor is available, decisions regarding alternative donors are transplant centre-dependent.
Historically, myeloablative conditioning regimens were used for patients with HLH who were treated with allogeneic HCT. Only 43-73% of patients survived in most of the larger reports published after 2002 (Table IV) (Baker et al, 2008; Cesaro et al, 2008; Henter et al, 2002; Horne et al, 2005; Marsh et al, 2010b; Ohga et al, 2010; Ouachee-Chardin et al, 2006; Yoon et al, 2010) . Hepatic veno-occlusive disease, pulmonary haemorrhage and death were common in the first 100 days following HCT. Patients with XIAP deficiency, who may have a particular susceptibility to myeloablative regimen complications, were observed to have a very poor survival rate of only 14% in an international survey (Marsh et al, 2013b) .
More recently, RIC approaches have been shown to improve survival for patients with HLH. Survival with a regimen consisting of alemtuzumab, fludarabine, and melphalan is generally greater than 70% (Table V) (Booth et al, 2011; Cooper et al, 2006 Cooper et al, , 2008 Marsh et al, 2015 Marsh et al, , 2010b Ono et al, 2017) . Again, patients with XIAP deficiency seem to have lower survival (Marsh et al, 2013b) , but survival appears to be greater than 80% when these patients are transplanted with RIC during HLH remission (Marsh et al, 2013b; Ono et al, 2017) .
Despite improved survival, RIC with alemtuzumab, fludarabine, and melphalan has unique complications. Patients transplanted with this regimen have a high likelihood of developing mixed donor and recipient chimerism following HCT (Marsh et al, , 2010b . This is of concern because decreases of whole blood donor chimerism to less than 20-30% are associated with risk of HLH relapse (Hartz et al, 2016) . At least 5% of patients treated with this approach require repeat HCT, and many patients are treated with additional cell products, including donor lymphocyte infusions or CD34+ selected haematopoietic cell boosts . Alemtuzumabcontaining preparative regimens are also associated with increased rates of viral reactivations. A prospective study of alemtuzumab, fludarabine and melphalan was recently conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), but the study data are currently unpublished. A modified regimen of alemtuzumab, fludarabine, melphalan, hydroxycarbamide and thiotepa has been utilized in 4 HLH patients who received umbilical cord grafts, and was successful in 3 of 4 patients (Patel et al, 2017) .
While RIC HCT with alemtuzumab, fludarabine and melphalan has improved survival among patients with HLH, it is clear that improvements are needed in order to make this approach more widely successful with regard to achieving sustained high levels of donor chimerism in more patients. Recent experience in London suggests that the use of peripheral blood stem cells may positively influence the probability of sustained high-level donor chimerism . Pharmacokinetic studies of alemtuzumab (Marsh et al, 2017b and melphalan are currently open, and precision-dosing approaches may result in high-level donor chimerism in more patients. Some centres are pursuing different approaches and are studying reduced toxicity approaches, including treosulfan or targeted low area under the concentration-time curve (AUC) busulfan (Gungor et al, 2014) based regimens. The results of these studies may alter the way transplant is approached for patients with HLH over the next 5-10 years.
Conclusions
In conclusion, great advances have been made over the last 20 years with regard to our understanding of primary HLH, with significant gains in diagnostics, treatment and transplant experience. Cutting edge diagnostics are now available to screen for genetic HLH diseases and should be more widely implemented. This will further improve patient care and outcomes and, in particular. should speed the time to treatment and the time to transplant, which is crucial for the prognosis. There is now good clinical experience on which to base routine treatment decisions for the up-front therapy of HLH with dexamethasone and etoposide or ATG. The authors consider these approaches to be the standard of care for patients who aren't enrolled in a clinical trial, though other Yoon et al (2010) 19 73% (5-year OS) Marsh et al (2010b) 14 43% (3-year OS) Ohga et al (2010) 43 (1 autologous) 65% (10-year OS) Booth et al (2011) 23 (XLP1) 83% (Various) Patel et al (2017) 10 60% (Various)
HCT, haematopoietic cell transplantation; HLH, haemophagocytic lymphohistiocytosis; OS, overall survival; XLP1, X-linked lymphoproliferative disease type 1. Marsh et al (2015) 91 70% (3-year EFS) Marsh et al (2014) 16 (XLP1) 80% (1-year OS) Booth et al (2011) 23 (XLP1) 79% (52-month follow-up †) Marsh et al (2013b) 11 (XLP2) 57% (1-year OS) Ono et al (2017) 8* (XLP2) 100% (3-year OS)
EFS, event-free survival; OS, overall survival; XLP1/2, X-linked lymphoproliferative disease type 1/2. *An additional patient was only followed for 5 months post HCT and not included in the analysis. †Follow up time is for the larger group of XLP patients in the report who received reduced intensity or myeloablative conditioning.
approaches can always be considered for individual patients. This may rapidly change over the next 5-10 years, and the results of several ongoing clinical trials are eagerly awaited, as the field is hopeful to find less toxic approaches to the management of HLH. Allogeneic HCT approaches have already changed over the last 20 years. RIC approaches have decreased severe toxicities and improved overall survival for patients with HLH, but improvements are still needed to gain sustained high level donor chimerism for more patients. Ongoing efforts to improve alemtuzumab, fludarabine and melphalan regimens and alternative studies of treosulfanand reduced intensity busulfan-based approaches will probably continue to improve outcomes for patients with primary HLH. All in all, the future is looking brighter for patients who suffer from primary HLH diseases.
Author contributions
R.A.M and E.H. both wrote the review.
Conflicts of interest
The authors declare that there are no financial conflicts of interest related to this article.
